These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Nasrallah HA; Fedora R; Morton R Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203 [TBL] [Abstract][Full Text] [Related]
26. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903 [TBL] [Abstract][Full Text] [Related]
27. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Hermanowicz S; Hermanowicz N Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168 [TBL] [Abstract][Full Text] [Related]
29. Parkinson's Disease Psychosis and the Marketing of Pimavanserin. Daeschler D; Fugh-Berman A Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164 [TBL] [Abstract][Full Text] [Related]
30. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863 [TBL] [Abstract][Full Text] [Related]
31. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis. Wilby KJ; Johnson EG; Johnson HE; Ensom MHH Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039 [TBL] [Abstract][Full Text] [Related]
32. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries. Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829 [TBL] [Abstract][Full Text] [Related]
33. Pimavanserin for the treatment of Parkinson's disease psychosis. Friedman JH Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069 [TBL] [Abstract][Full Text] [Related]
34. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis. Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395 [No Abstract] [Full Text] [Related]
35. Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval. Schubmehl S; Sussman J Am J Geriatr Psychiatry; 2018 Oct; 26(10):1007-1011. PubMed ID: 30072306 [TBL] [Abstract][Full Text] [Related]
36. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis. Isaacson SH; Coate B; Norton J; Stankovic S J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320 [TBL] [Abstract][Full Text] [Related]
39. Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series. Rothenberg KG; McRae SG; Dominguez-Colman LM; Shutes-David A; Tsuang DW Am J Case Rep; 2023 Sep; 24():e939806. PubMed ID: 37775968 [TBL] [Abstract][Full Text] [Related]
40. Clozapine: Efficacy for Parkinson Disease psychosis in patients refractory to pimavanserin. Thames BH; Ondo WG Parkinsonism Relat Disord; 2023 Apr; 109():105356. PubMed ID: 36905718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]